Literature DB >> 11096722

Convulsive Status Epilepticus.

.   

Abstract

Generalized convulsive status epilepticus (GCSE) is a medical emergency that must be treated rapidly and aggressively to prevent neuronal damage. Treatment should be initiated with intravenous lorazepam, 0.1 mg/kg, given at a rate of no more than 2 mg/min. If convulsions persist for more than 10 minutes or recur more than 20 minutes after lorazepam therapy is started, then fosphenytoin (20 mg of phenytoin equivalents per kilogram) should be infused at a rate of no more than 150 mg/min. If convulsions still continue, intravenous general anesthesia with pentobarbital, benzodiazepine drip, or propofol should be initiated after respiratory support has been established. All patients with GCSE who do not recover consciousness should be monitored with electroencephalography (EEG), and any residual epileptiform activity on EEG, including periodic epileptiform discharges (PEDs), should be considered evidence of continuing GCSE and treated aggressively.

Entities:  

Year:  1999        PMID: 11096722     DOI: 10.1007/s11940-999-0025-5

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  32 in total

1.  Pentobarbital anesthesia for status epilepticus.

Authors:  J H Fischer; D L Raineri
Journal:  Clin Pharm       Date:  1987-08

2.  Current concepts in neurology: management of status epilepticus.

Authors:  A V Delgado-Escueta; C Wasterlain; D M Treiman; R J Porter
Journal:  N Engl J Med       Date:  1982-06-03       Impact factor: 91.245

Review 3.  Status epilepticus: epidemiologic considerations.

Authors:  W A Hauser
Journal:  Neurology       Date:  1990-05       Impact factor: 9.910

Review 4.  Current treatment strategies in selected situations in epilepsy.

Authors:  D M Treiman
Journal:  Epilepsia       Date:  1993       Impact factor: 5.864

5.  Epileptic brain damage: the role of systemic factors that modify cerebral energy metabolism.

Authors:  G Blennow; J B Brierley; B S Meldrum; B K Siesjö
Journal:  Brain       Date:  1978-12       Impact factor: 13.501

6.  Diazepam by continuous intravenous infusion for status epilepticus in anticonvulsant hypersensitivity syndrome.

Authors:  R J Bertz; D L Howrie
Journal:  Ann Pharmacother       Date:  1993-03       Impact factor: 3.154

7.  Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin.

Authors:  T J O'Brien; G D Cascino; E L So; D R Hanna
Journal:  Neurology       Date:  1998-10       Impact factor: 9.910

8.  Pentobarbital treatment of refractory status epilepticus.

Authors:  M C Rashkin; C Youngs; P Penovich
Journal:  Neurology       Date:  1987-03       Impact factor: 9.910

9.  Increased damage after ischemic stroke in patients with hyperglycemia with or without established diabetes mellitus.

Authors:  W A Pulsinelli; D E Levy; B Sigsbee; P Scherer; F Plum
Journal:  Am J Med       Date:  1983-04       Impact factor: 4.965

10.  [Intravenous valproic acid administration in status epilepticus].

Authors:  P Czapiński; A Terczyński
Journal:  Neurol Neurochir Pol       Date:  1998 Jan-Feb       Impact factor: 1.621

View more
  5 in total

1.  Status epilepticus.

Authors:  Panayiotis N Varelas; Marek A Mirski
Journal:  Curr Neurol Neurosci Rep       Date:  2009-11       Impact factor: 5.081

Review 2.  Status epilepticus: an update.

Authors:  Panayiotis N Varelas; Marianna V Spanaki; Marek A Mirski
Journal:  Curr Neurol Neurosci Rep       Date:  2013-07       Impact factor: 5.081

3.  The efficacy of intravenous sodium valproate and phenytoin as the first-line treatment in status epilepticus: a comparison study.

Authors:  Somsak Tiamkao; Kittisak Sawanyawisuth; Alongkorn Chancharoen
Journal:  BMC Neurol       Date:  2013-07-27       Impact factor: 2.474

4.  Fosphenytoin for the treatment of status epilepticus: an evidence-based assessment of its clinical and economic outcomes.

Authors:  Andrew Thomson
Journal:  Core Evid       Date:  2005-03-31

Review 5.  The promise of new antiepileptic drugs.

Authors:  John S Duncan
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.